Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

References

• European Association for the Study of the LiverElectronic address: [email protected]; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinomaJ Hepatol201869118223629628281
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverElectronic address: [email protected]. EASL Clinical Practice Guidelines: liver transplantationJ Hepatol201664243348526597456
   PubMed Web of Science ®Google Scholar
• MazzaferroVLlovetJMMiceliRPredicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysisLancet Oncol2009101354319058754
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverElectronic address: [email protected], European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018J Hepatol201869246151129650333
   PubMed Web of Science ®Google Scholar
• HerreroJISangroBPardoFLiver transplantation in patients with hepatocellular carcinoma across Milan criteriaLiver Transpl200814327227818306328
   PubMed Web of Science ®Google Scholar
• YaoFYFerrellLBassNMLiver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survivalHepatology20013361394140311391528
   PubMed Web of Science ®Google Scholar
• Guerrero-MisasMRodríguez-PerálvarezMde La MataMStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationWorld J Hepatol20157464966125866602
   PubMedGoogle Scholar
• TsuchiyaNSawadaYEndoISaitoKUemuraYNakatsuraTBiomarkers for the early diagnosis of hepatocellular carcinomaWorld J Gastroenterol20152137105731058326457017
   PubMed Web of Science ®Google Scholar
• CharrièreBMaulatCSucBMuscariFContribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinomaWorld J Hepatol201682188189027478538
   PubMedGoogle Scholar
• ChanSLMoFKJohnsonPJNew utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapyJ Clin Oncol200927344645219064965
   PubMed Web of Science ®Google Scholar
• JohnsonPJThe role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinomaClin Liver Dis20015114515911218912
   PubMedGoogle Scholar
• BruixJShermanMAmerican association for the study of liver diseasesManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
   PubMed Web of Science ®Google Scholar
• TosoCAsthanaSBigamDLShapiroAMKnetemanNMReassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients databaseHepatology200949383283819152426
   PubMed Web of Science ®Google Scholar
• MaileyBArtinyanAKhaliliJEvaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancerArch Surg20111461263321242442
   PubMedGoogle Scholar
• MuscariFGuinardJPKamarNPeronJMOtalPSucBImpact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinomaWorld J Surg20123681824183122532309
   PubMed Web of Science ®Google Scholar
• MaWJWangHYTengLSCorrelation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomyWorld J Surg Oncol20131121223981851
   PubMed Web of Science ®Google Scholar
• YamashitaYIImaiKYusaTMicrovascular invasion of single small hepatocellular carcinoma ≤3 cm: predictors and optimal treatmentsAnn Gastroenterol Surg20182319720329863190
   PubMed Web of Science ®Google Scholar
• BerryKIoannouGNSerum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinomaLiver Transpl201319663464523536495
   PubMed Web of Science ®Google Scholar
• TosoCMeebergGHernandez-AlejandroRTotal tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validationHepatology201562115816525777590
   PubMed Web of Science ®Google Scholar
• CiccarelliOLaiQGoffettePLiver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteriaTranspl Int201225886787522716073
   PubMed Web of Science ®Google Scholar
• SapisochinGGoldaracenaNLaurenceJMThe extended Toronto criteria for liver transplantation in patients with hepato-cellular carcinoma: a prospective validation studyHepatology20166462077208827178646
   PubMed Web of Science ®Google Scholar
• LaiQIesariSMelandroFMenniniGRossiMLerutJThe growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolutionTransl Gastroenterol Hepatol201727229034345
   PubMed Web of Science ®Google Scholar
• HameedBMehtaNSapisochinGRobertsJPYaoFYAlpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteriaLiver Transpl201420894595124797281
   PubMed Web of Science ®Google Scholar
• DuvouxCRoudot-ThoravalFDecaensTLiver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteriaGastroenterology2012143498699422750200
   PubMed Web of Science ®Google Scholar
• JangJWYouCRKimCWBenefit of downsizing hepatocellular carcinoma in a liver transplant populationAliment Pharmacol Ther201031341542319821808
   PubMed Web of Science ®Google Scholar
• LiebmanHAFurieBCTongMJDes-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinomaN Engl J Med198431022142714316201741
   PubMed Web of Science ®Google Scholar
• ZhuRYangJXuLDiagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma: a meta-analysisGastroen-terol Res Pract20142014529314
   PubMed Web of Science ®Google Scholar
• XingHYanCChengLClinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinomaTumour Biol2016137121544756
   Google Scholar
• SongPFengXZhangKPerspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in ChinaHepatobiliary Surg Nutr20132422723124570947
   PubMedGoogle Scholar
• MeguroMMizuguchiTNishidateTPrognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patientsWorld J Gastroenterol201521164933494525945007
   PubMed Web of Science ®Google Scholar
• LimTSKimDYHanKHCombined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patientsScand J Gastroenterol201651334435326340708
   PubMed Web of Science ®Google Scholar
• KimJMHyuckCKwonDProtein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinomaWorld J Surg20133761371137823443153
   PubMed Web of Science ®Google Scholar
• IguchiTShirabeKAishimaSNew pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantationTransplantation20159961236124225427164
   PubMed Web of Science ®Google Scholar
• ShirabeKItohSYoshizumiTThe predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombinJ Surg Oncol200795323524017323337
   PubMed Web of Science ®Google Scholar
• PotéNCauchyFAlbuquerqueMPerformance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasionJ Hepatol201562484885425450201
   PubMed Web of Science ®Google Scholar
• CarrBIKankeFWiseMSatomuraSClinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United StatesDig Dis Sci200752377678217253135
   PubMed Web of Science ®Google Scholar
• MaXLZhuJWuJSignificance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinomaOncol Lett20181568396840429805574
   PubMed Web of Science ®Google Scholar
• TodoSFurukawaHTadaMJapanese Liver Transplantation Study GroupExtending indication: role of living donor liver transplantation for hepatocellular carcinomaLiver Transpl20071311 Suppl 2S48S5417969069
   PubMed Web of Science ®Google Scholar
• ShindohJSugawaraYNagataREvaluation methods for pre-transplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinomaTranspl Int201427439139824472068
   PubMed Web of Science ®Google Scholar
• PommergaardHCBurcharthJRosenbergJRasmussenASerologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysisTransplant Rev (Orlando)201630317117727118303
   PubMedGoogle Scholar
• LaiQIesariSLevi SandriGBLerutJDes-gamma-carboxy pro-thrombin in hepatocellular cancer patients waiting for liver transplant: a systematic review and meta-analysisInt J Biol Markers2017324e370e37428561879
   PubMed Web of Science ®Google Scholar
• LeeHWSongGWLeeSGPatient selection by tumor markers in liver transplantation for advanced hepatocellular carcinomaLiver Transpl20182491243125129575509
   PubMed Web of Science ®Google Scholar
• TaketomiASanefujiKSoejimaYImpact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantationTransplantation200987453153719307789
   PubMed Web of Science ®Google Scholar
• TakadaYUemotoSLiver transplantation for hepatocellular carcinoma: the Kyoto experienceJ Hepatobiliary Pancreat Sci201017552753219707711
   PubMed Web of Science ®Google Scholar
• HalazunKJHardyMARanaAANegative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinomaAnn Surg2009250114115119561458
   PubMed Web of Science ®Google Scholar
• LimayeARClarkVSoldevila-PicoCNeutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinomaHepatol Res201343775776423193965
   PubMed Web of Science ®Google Scholar
• XiaoGQLiuCLiuDLYangJYYanLNNeutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantationWorld J Gastroenterol201319458398840724363533
   PubMed Web of Science ®Google Scholar
• LaiQCastro SantaERico JuriJMPinheiroRSLerutJNeutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancerTranspl Int2014271324124118272
   PubMed Web of Science ®Google Scholar
• ZhaoYSiGZhuFPrognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysisOncotarget2017814228542286228206965
   PubMedGoogle Scholar
• ManoYYoshizumiTYugawaKLymphocyte-to-monocyte ratio is a predictor of survival after liver transplantation for hepatocellular carcinomaLiver Transpl201824111603161129893464
   PubMed Web of Science ®Google Scholar
• QiXLiJDengHLiHSuCGuoXNeutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a systematic review and meta-analysis of observational studiesOncotarget2016729452834530127304193
   PubMed Web of Science ®Google Scholar
• XiaWKeQWangYPredictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantationWorld J Surg Oncol2015136025885777
   PubMed Web of Science ®Google Scholar
• ZhengZZhouLGaoSYangZYaoJZhengSPrognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysisInt J Med Sci201310665366423569429
   PubMed Web of Science ®Google Scholar
• AnHJJangJWBaeSHSerum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinomaLiver Transpl201218121406141422821639
   PubMed Web of Science ®Google Scholar
• NaGHKimDGHanJHInflammatory markers as selection criteria of hepatocellular carcinoma in living-donor liver transplantationWorld J Gastroenterol201420216594660124914382
   PubMed Web of Science ®Google Scholar
• KimYKKimSHLeeSDHongSKParkSJPretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinomaTransplant Proc201547368669325891712
   PubMed Web of Science ®Google Scholar
• ChoiJYJungSWKimHYDiagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFPWorld J Gastroenterol201319333934623372355
   PubMed Web of Science ®Google Scholar
• ChengJWangWZhangYPrognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysisPLoS One201491e8701124498011
   PubMed Web of Science ®Google Scholar
• WanHGXuHGuYMWangHXuWZuMHComparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysisClin Res Hepatol Gastroenterol201438670671425034355
   PubMed Web of Science ®Google Scholar
• BeckebaumSChenXSotiropoulosGCRole of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resectionTransplant Proc20084093182318419010227
   PubMed Web of Science ®Google Scholar
• SieghartWWangXSchmidKOsteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteriaJ Hepatol2011541899720970216
   PubMed Web of Science ®Google Scholar
• LaiQAvolioAWGraziadeiIAlpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantationLiver Transpl201319101108111823873764
   PubMed Web of Science ®Google Scholar
• VibertEAzoulayDHotiEProgression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factorAm J Transplant201010112913720070666
   PubMed Web of Science ®Google Scholar
• VitaleAVolkMLde FeoTMA method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting listJ Hepatol201460229029724161408
   PubMed Web of Science ®Google Scholar
• GuerriniGPPinelliDMariniEValue of HCC-MELD score in patients with hepatocellular carcinoma undergoing liver transplantationProg Transplant2018281636929251164
   PubMed Web of Science ®Google Scholar
• TosoCDupuis-LozeronEMajnoPA model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting listHepatology201256114915622271250
   PubMed Web of Science ®Google Scholar
• TosoCMajnoPBerneyTMorelPMenthaGCombescureCValidation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting listTranspl Int201427768669524649861
   PubMed Web of Science ®Google Scholar
• CesconMCucchettiARavaioliMPinnaADHepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rateJ Hepatol201358360961823041304
   PubMed Web of Science ®Google Scholar
• ShakerMKMontasserIFSakrMEfficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in EgyptJ Hepatocell Carcinoma20185293629520343
   PubMed Web of Science ®Google Scholar
• ParikhNDWaljeeAKSingalAGDownstaging hepatocellular carcinoma: A systematic review and pooled analysisLiver Transpl20152191142115225981135
   PubMed Web of Science ®Google Scholar
• GyöriGPFelsenreichDMSilberhumerGRSolimanTBerlakovichGAMultimodality locoregional treatment strategies for bridging HCC patients before liver transplantationEur Surg201749523624329104589
   PubMed Web of Science ®Google Scholar
• MazzaferroVSquaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approachHepatology20166351707171726703761
   PubMed Web of Science ®Google Scholar
• PommergaardHCRostvedAAAdamRLocoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant RegistryTranspl Int201831553153929380442
   PubMed Web of Science ®Google Scholar
• YaoFYKerlanRKHiroseRExcellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysisHepatology200848381982718688876
   PubMed Web of Science ®Google Scholar
• OttoGHerberSHeiseMResponse to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinomaLiver Transpl20061281260126716826556
   PubMed Web of Science ®Google Scholar
• RobertsJPVenookAKerlanRYaoFHepatocellular carcinoma: Ablate and wait versus rapid transplantationLiver Transpl201016892592920658555
   PubMed Web of Science ®Google Scholar
• ClavienPALesurtelMBossuytPMRecommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportLancet Oncol2012131e112222047762
   PubMed Web of Science ®Google Scholar
• CilloUBurraPMazzaferroVA multistep, consensus-based approach to organ allocation in liver transplantation: toward a “Blended Principle Model”Am J Transplant201515102552256126274338
   PubMed Web of Science ®Google Scholar
• MarvinMRFergusonNCannonRMJonesCMBrockGNMELDEQ: An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinomaLiver Transpl201521561262225694099
   PubMed Web of Science ®Google Scholar
• YuSCLoDYIpCBLiewCTLeungTWLauWYDoes percutaneous liver biopsy of hepatocellular carcinoma cause hematogenous dissemination? An in vivo study with quantitative assay of circulating tumor DNA using methylation-specific real-time polymerase chain reactionAJR Am J Roentgenol2004183238338515269029
   PubMed Web of Science ®Google Scholar
• SilvaMAHegabBHydeCGuoBBuckelsJAMirzaDFNeedle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysisGut200857111592159618669577
   PubMed Web of Science ®Google Scholar
• Rodríguez-PerálvarezMLuongTVAndreanaLMeyerTDhillonAPBurroughsAKA systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variabilityAnn Surg Oncol201320132533923149850
   PubMed Web of Science ®Google Scholar
• DubayDSandroussiCSandhuLLiver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterionAnn Surg2011253116617221294289
   PubMed Web of Science ®Google Scholar
• Martins-FilhoSNPaivaCAzevedoRSAlvesVAFHistological grading of hepatocellular carcinoma-a systematic review of literatureFront Med20174193
   Web of Science ®Google Scholar
• ZiolMPotéNAmaddeoGMacrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevanceHepatology201868110311229281854
   PubMed Web of Science ®Google Scholar
• JakubovicBDJothySGlypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinomaExp Mol Pathol200782218418917258707
   PubMed Web of Science ®Google Scholar
• ShafizadehNFerrellLDKakarSUtility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrumMod Pathol20082181011101818536657
   PubMed Web of Science ®Google Scholar
• WangHLAnatelliFZhaiQJAdleyBChuangSTYangXJGlypi-can-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesionsArch Pathol Lab Med2008132111723172818976006
   PubMed Web of Science ®Google Scholar
• YoritaKTakahashiNTakaiHPrognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinomaLiver Int201131112013120964802
   PubMed Web of Science ®Google Scholar
• ShirakawaHSuzukiHShimomuraMGlypican-3 expression is correlated with poor prognosis in hepatocellular carcinomaCancer Sci200910081403140719496787
   PubMed Web of Science ®Google Scholar
• LoRCNgIORcLIoNHepatocellular tumors: immunohistochemical analyses for classification and prognosticationChin J Cancer Res201123424525323359751
   PubMed Web of Science ®Google Scholar
• FerrínGAguilar-MeleroPRodríguez-PerálvarezMMontero-ÁlvarezJLde La MataMBiomarkers for hepatocellular carcinoma: diagnostic and therapeutic utilityHepat Med2015711025926760
   PubMedGoogle Scholar
• YangHXiongFXLinMYangYNieXZhouRLLAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinomaJ Cancer Res Clin Oncol2010136227528119690886
   PubMed Web of Science ®Google Scholar
• ItohSMaedaTShimadaMRole of expression of focal adhesion kinase in progression of hepatocellular carcinomaClin Cancer Res20041082812281715102689
   PubMed Web of Science ®Google Scholar
• IguchiTAishimaSUmedaKFascin expression in progression and prognosis of hepatocellular carcinomaJ Surg Oncol2009100757557919697358
   PubMed Web of Science ®Google Scholar
• RikimaruTTaketomiAYamashitaYClinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinomaOncology2007721-2697418004079
   PubMed Web of Science ®Google Scholar
• SongWLiHTaoKExpression and clinical significance of the stem cell marker CD133 in hepatocellular carcinomaInt J Clin Pract20086281212121818479363
   PubMed Web of Science ®Google Scholar
• YunJPMiaoJChenGGIncreased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parametersBr J Cancer200796347748417245342
   PubMed Web of Science ®Google Scholar
• MaHLiangXChenYDecreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinomaInt J Cancer2011128477177720473897
   PubMed Web of Science ®Google Scholar
• GaoQWangXYQiuSJOverexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinomaClin Cancer Res200915397197919188168
   PubMed Web of Science ®Google Scholar
• ZhaiBYanHXLiuSQChenLWuMCWangHYReduced expression of E-cadherin/catenin complex in hepatocellular carcinomasWorld J Gastroenterol200814375665567318837082
   PubMed Web of Science ®Google Scholar
• YuBYangXXuYElevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomasJ Hepatol200950594895719303159
   PubMed Web of Science ®Google Scholar
• TungEKMakCKFatimaSClinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinomaLiver Int201131101494150421955977
   PubMed Web of Science ®Google Scholar
• XieHSongJduRPrognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinomaDig Liver Dis200739216717217161983
   PubMedGoogle Scholar
• KoritaPVWakaiTShiraiYOverexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinomaHum Pathol200839121777178318701136
   PubMed Web of Science ®Google Scholar
• KornbergAKüpperBThrumKIncreased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patientsTransplant Proc20094162561256319715974
   PubMed Web of Science ®Google Scholar
• CheungTTChanSCHoCLCan positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?Liver Transpl201117101218122521688383
   PubMed Web of Science ®Google Scholar
• YangSHSuhKSLeeHWThe role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patientsLiver Transpl200612111655166016964589
   PubMed Web of Science ®Google Scholar
• LeeJWPaengJCKangKWPrediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinomaJ Nucl Med200950568268719372474
   PubMed Web of Science ®Google Scholar
• LeeSDKimSHKimYK(18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinomaTranspl Int2013261506023106431
   PubMed Web of Science ®Google Scholar
• KornbergAKupperBTannapfelAPatients with non-[18 F] fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantationLiver Transpl20128115361
   Web of Science ®Google Scholar
• HongGSuhKSSuhSWAlpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantationJ Hepatol201664485285926658686
   PubMed Web of Science ®Google Scholar
• NelIDavidPGerkenGGSchlaakJFHoffmannACRole of circulating tumor cells and cancer stem cells in hepatocellular carcinomaHepatol Int20148332132926202635
   PubMed Web of Science ®Google Scholar
• NgCKYdi CostanzoGGTerraccianoLMPiscuoglioSCirculating cell-free DNA in hepatocellular carcinoma: current insights and outlookFront Med (Lausanne)201857829632864
   PubMed Web of Science ®Google Scholar
• HuangAZhangXZhouSLPlasma circulating cell-free DNA integrity as a promising biomarker for diagnosis and surveillance in patients with hepatocellular carcinomaJ Cancer20167131798180327698918
   PubMed Web of Science ®Google Scholar
• YinCQYuanCHQuZGuanQChenHWangFBLiquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkersDis Markers2016201614278491127403030
   PubMed Web of Science ®Google Scholar
• OkajimaWKomatsuSIchikawaDLiquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acidsWorld J Gastroenterol201723315650566828883691
   PubMed Web of Science ®Google Scholar
• ZhouJHuangAYangXRLiquid biopsy and its potential for management of hepatocellular carcinomaJ Gastrointest Cancer201647215716726969471
   PubMedGoogle Scholar
• Rodríguez-PerálvarezMTsochatzisENaveasMCReduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinomaJ Hepatol20135961193119923867318
   PubMed Web of Science ®Google Scholar
• ZhangYLiJCaoLXuWYinZCirculating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectivesSemin Oncol201239444946022846862
   PubMed Web of Science ®Google Scholar
• Paterlini-BréchotPVonaGBréchotCCirculating tumorous cells in patients with hepatocellular carcinoma. Clinical impact and future directionsSemin Cancer Biol200010324124910936072
   PubMed Web of Science ®Google Scholar
• GuoWSunYFShenMNCirculating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinomaClin Cancer Res20182492203221329374055
   PubMed Web of Science ®Google Scholar
• Sánchez-LorencioMIRamirezPSaenzLComparison of two types of liquid biopsies in patients with hepatocellular carcinoma awaiting orthotopic liver transplantationTransplant Proc20154792639264226680058
   PubMed Web of Science ®Google Scholar
• YamashitaTForguesMWangWEpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinomaCancer Res20086851451146118316609
   PubMed Web of Science ®Google Scholar
• NelIBabaHAErtleJIndividual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinomaTransl Oncol20136442042823908685
   PubMed Web of Science ®Google Scholar
• VonaGEstepaLBéroudCImpact of cytomorphological detection of circulating tumor cells in patients with liver cancerHepatology200439379279714999698
   PubMed Web of Science ®Google Scholar
• XuWCaoLChenLIsolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategyClin Cancer Res201117113783379321527564
   PubMed Web of Science ®Google Scholar
• SchulzeKGaschCStauferKPresence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinomaInt J Cancer201313392165217123616258
   PubMed Web of Science ®Google Scholar
• SunYFXuYYangXRCirculating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resectionHepatology20135741458146823175471
   PubMed Web of Science ®Google Scholar
• KelleyRKMagbanuaMJButlerTMCirculating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controlsBMC Cancer20151520625884197
   PubMed Web of Science ®Google Scholar
• RamirezPSáenzLCascales-CamposPAOncological evaluation by positron-emission tomography, circulating tumor cells and alpha fetoprotein in patients with hepatocellular carcinoma on the waiting list for liver transplantationTransplant Proc20164892962296527932119
   PubMed Web of Science ®Google Scholar
• von FeldenJSchulzeKKrechTCirculating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resectionOncotarget2017852899788998729163804
   PubMedGoogle Scholar
• GuoWYangXRSunYFClinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platformClin Cancer Res201420184794480525009297
   PubMed Web of Science ®Google Scholar
• FanJLYangYFYuanCHChenHWangFBCirculating tumor cells for predicting the prognostic of patients with hepatocellular carcinoma: a meta analysisCell Physiol Biochem201537262964026344495
   PubMedGoogle Scholar
• SunCLiaoWDengZThe diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: a meta-analysisMedicine20179629e751328723763
   PubMed Web of Science ®Google Scholar
• XueFShiSZhangZApplication of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantationOncol Lett20181545481548829552189
   PubMed Web of Science ®Google Scholar
• WangSZhengYLiuJHuoFZhouJAnalysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantationJ Investig Med2018665166
   Web of Science ®Google Scholar
• HuangZHuaDHuYQuantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinomaPathol Oncol Res201218227127621779787
   PubMed Web of Science ®Google Scholar
• OnoAFujimotoAYamamotoYCirculating tumor DNA analysis for liver cancers and Its usefulness as a liquid biopsyCell Mol Gastroenterol Hepatol20151551653428210698
   PubMedGoogle Scholar
• LiaoWYangHXuHNoninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencingOncotarget2016726404814049027248174
   PubMed Web of Science ®Google Scholar
• ChanKCLaiPBMokTSQuantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinomaClin Chem20085491528153618653827
   PubMed Web of Science ®Google Scholar
• DivellaRLacalamitaRTommasiSPAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesisAnticancer Res2008281A22322818383849
   PubMed Web of Science ®Google Scholar
• RenNYeQHQinLXZhangBHLiuYKTangZYCirculating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patientsWorld J Gastroenterol200612243911391416804981
   PubMed Web of Science ®Google Scholar
• TokuhisaYIizukaNSakaidaICirculating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinomaBr J Cancer200797101399140317940509
   PubMed Web of Science ®Google Scholar
• PiciocchiMCardinRVitaleACirculating free DNA in the progression of liver damage to hepatocellular carcinomaHepatol Int2013741050105726202034
   PubMed Web of Science ®Google Scholar
• IkedaSTsigelnyIFSkjevikÅANext-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinomaOncologist201823558659329487225
   PubMed Web of Science ®Google Scholar
• Zucman-RossiJMolecular classification of hepatocellular carcinomaDig Liver Dis201042Suppl 3S235S24120547309
   PubMedGoogle Scholar
• PatelASunWMolecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and futureCurr Treat Options Oncol201415338039424838298
   PubMed Web of Science ®Google Scholar
• HuangAZhaoXYangXRCircumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinomaJ Hepatol201767229330128323123
   PubMed Web of Science ®Google Scholar